| URL | https://www.reuters.com/article/us-novo-nordisk-us |
| Source | Reuters |
| Date Published | 08/06/2019 |
| Author Name | Jacob Gronholt-Pedersen |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Novo Nordisk |
| Parent company | Novo Nordisk |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2019 |
| Country(ies) from which reshored: | Denmark |
| City reshored to: | Treyburn |
| State(s) reshored to: | NC |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | new diabetes drug |
| What domestic positive factors made reshoring more attractive? | Proximity to customers/market, Under-utilized capacity |